**Core Concept**
The combination of certain drugs with carbonic anhydrase inhibitors can lead to an increased risk of renal stone formation due to alterations in urinary pH and calcium excretion. This is particularly relevant in the context of metabolic alkalosis, which can occur with carbonic anhydrase inhibition.

**Why the Correct Answer is Right**
The development of renal stones is most closely associated with the use of thiazide diuretics in combination with carbonic anhydrase inhibitors. Thiazides increase the reabsorption of calcium in the distal convoluted tubule, leading to hypercalciuria. When combined with carbonic anhydrase inhibitors, which can cause metabolic alkalosis and further increase calcium reabsorption, the risk of renal stone formation is significantly heightened. This is particularly relevant in patients with a history of renal stones or those with a predisposition to hypercalciuria.

**Why Each Wrong Option is Incorrect**
**Option A:** Loop diuretics, such as furosemide, do not significantly increase the risk of renal stone formation when used with carbonic anhydrase inhibitors. Loop diuretics primarily act on the loop of Henle, leading to increased sodium and chloride excretion, without a significant impact on calcium reabsorption.
**Option B:** Potassium-sparing diuretics, such as spironolactone, do not increase the risk of renal stone formation when used with carbonic anhydrase inhibitors. These agents primarily act on the collecting duct, leading to potassium retention and increased calcium excretion, but do not significantly impact renal stone formation risk.
**Option C:** This option is incorrect as it is not a valid choice.

**Clinical Pearl / High-Yield Fact**
When using carbonic anhydrase inhibitors, it is essential to monitor urinary calcium excretion and adjust the treatment plan accordingly to minimize the risk of renal stone formation.

**Correct Answer:** C. Thiazide diuretics.